Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Irvine
Dates
study started
completion around

Description

Summary

This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma

Official Title

An Open-label, Multi-center, Non-randomized Phase I Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ONO-4685 Given as Monotherapy in Patients With Relapsed or Refractory T Cell Lymphoma

Keywords

Relapsed or Refractory T Cell Lymphoma, ONO-4685, PD-1, CD3, Bispecific antibody, PTCL, AITL, PTCL-NOS, nodal PTCL with TFH, FTCL, CTCL, MF, SS, Lymphoma, T-Cell Lymphoma, Lymphoma, T-Cell, Peripheral, ONO-4685 monotherapy

Eligibility

Locations

  • University of California Irvine Medical Center - Chao Family Comprehensive Cancer Center accepting new patients
    Orange California 92868 United States
  • Stanford Cancer Institute accepting new patients
    Palo Alto California 94304 United States
  • City of Hope accepting new patients
    Duarte California 91010 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Ono Pharmaceutical Co. Ltd
ID
NCT05079282
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 217 study participants
Last Updated